| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 242.7 | 156.7 |
| Profit before tax | -110.1 | -128.4 |
| Net income | -110.0 | -128.6 |
| EPS (diluted, $ a share) | $-0.66 | $-0.80 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +54.9% |
|---|---|
| Operating margin | -53.8% |
10-Q filed with the SEC, NASDAQ: IONS. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Ionis Pharmaceuticals Inc: key numbers
- Share price
- $28.01Close, Nov 16
- Market cap
- $4.66B
- Shares outstanding
- 166.55MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Ionis Pharmaceuticals Inc
All →Ionis Pharmaceuticals Insider Michael R. Hayden Buys $148K of Stock
Michael R. Hayden bought 5,000 shares of Ionis Pharmaceuticals Inc at $29.64 a share, worth $148K in total on Nov 10, 2026. Shares held after the trade: 27,000 (+22.7%).
- Value
- $148K
- Shares
- 5,000
- Price
- $29.64
- Holding change
- +22.7%
- Trade date
- Nov 10, 2026
Ionis Pharmaceuticals Financial Results
Ionis Pharmaceuticals reported Q3 2026 total revenue of $243 million, a 55% increase year-over-year, driven by commercial revenue and R&D partnerships. The company lowered its 2026 product sales guidance for TRYNGOLZA due to a slower-than-expected launch ramp in the sHTG population, while reaffirming total revenue and cash guidance. Ionis ended the quarter with $1.9 billion in cash and short-term investments.
- Term
- Q3 2026
“TRYNGOLZA, our first launch in a large indication, represents a new treatment paradigm for the underserved sHTG population. While initial sales progress has been more gradual than anticipated, we are encouraged by the underlying launch fundamentals. Importantly, we have identified clear opportunities to improve performance, and we remain confident in TRYNGOLZA's long-term growth potential.”
Brett P. Monia, Ph.D., chief executive officer of Ionis
“In the third quarter, we generated higher quarter-over-quarter commercial revenue and substantial R&D revenue from partnered medicines while continuing to invest in our innovative wholly owned pipeline. Our commercial revenue growth was driven by DAWNZERA, which continues to gain momentum, supporting our confidence in achieving full-year DAWNZERA product sales guidance.”
Elizabeth L. Hougen, chief financial officer of Ionis
Ionis Pharmaceuticals Clinical Trial Data
Ionis Pharmaceuticals and its partner Roche announced positive Phase 3 IMAgINATION study results for sefaxersen in patients with IgA nephropathy. The trial met its primary endpoint, demonstrating a statistically significant 43.1% reduction in proteinuria compared to placebo at 37 weeks, with a safety profile consistent with earlier studies.
- Counterparty
- Roche
“These data support our belief that sefaxersen is uniquely positioned to treat IgA nephropathy, demonstrating significant and clinically meaningful reduction in proteinuria and offering the potential to help reduce the need for long-term dialysis or kidney transplantation.”
Brett P. Monia, Ph.D., chief executive officer, Ionis
“Sefaxersen is a powerful example of the broad impact of Ionis' innovative science, and based on these positive data, we believe it has the potential to be an important new treatment option for people living with IgA nephropathy.”
Brett P. Monia, Ph.D., chief executive officer, Ionis
Ionis Pharmaceuticals Regulatory Approval
Ionis Pharmaceuticals' partner GSK received FDA approval for HIBSAGO (bepirovirsen) for the treatment of chronic hepatitis B (CHB) in adult patients without cirrhosis. The approval, granted under priority review and Breakthrough Therapy Designation, is based on Phase 3 B-Well trials showing a 19% functional cure rate compared to less than 1% for standard of care. Ionis is eligible to receive regulatory and sales milestone payments plus tiered royalties of 10-12% on net sales.
- Counterparty
- GSK
Ionis Pharmaceuticals EVP, Chief Human Resources Ofc Shannon L. Devers Sells $59.1K of Stock
Shannon L. Devers, EVP, Chief Human Resources Ofc, sold 1,357 shares of Ionis Pharmaceuticals Inc at $43.54 a share, worth $59.1K in total on Oct 16, 2026. Shares held after the trade: 17,811 (-7.1%).
- Value
- $59.1K
- Shares
- 1,357
- Price
- $43.54
- Role
- EVP, Chief Human Resources Ofc
- Holding change
- -7.1%
- Trade date
- Oct 16, 2026
Ionis Pharmaceuticals Clinical Trial Data
Ionis and partner Roche announced positive interim results from the Phase 3 IMAgINATION study of sefaxersen in adults with IgA nephropathy (IgAN). The study met its primary endpoint, demonstrating statistically significant and clinically meaningful reductions in proteinuria compared to placebo at 37 weeks.
- Counterparty
- Roche Holding Ltd.
“With these positive interim results, sefaxersen is positioned to directly address a primary driver of IgAN-related kidney damage, offering the potential to help slow disease progression and potentially reduce the long-term need for dialysis or kidney transplantation.”
Brett P. Monia, Ph.D., chief executive officer, Ionis